COVID-19 Archive — Page 12 of 35

The team studying smell and taste loss associated with COVID-19 includes, from left, Rakesh Chandra, MD, Justin Turner, MD, Timothy Trone, MD, and Nikita Chapurin, MD, MHS.
September 23, 2021

Study tracks smell, taste loss associated with COVID

Vanderbilt researchers are studying ways to better evaluate and predict who is at risk of persistent smell and taste loss after COVID-19 infection.

By Emily Stembridge
Portrait of Jeff Balser, MD, PhD, wearing glasses, a dark suit, white shirt, and patterned tie.
September 22, 2021

Rounds: Hard conversations

By Doug Campbell
Illustration of several spherical virus particles with brown textured surfaces and numerous translucent yellow spike-like projections, shown against a dark reddish-brown background.
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

By Bill Snyder
Three-dimensional illustration of a coronavirus particle with a textured gray spherical surface, red spike proteins, and smaller yellow surface structures; blurred particles appear in the background.
September 15, 2021

Older age, chronic co-morbidities associated with more severe COVID disease in children

Vanderbilt research found that multiple factors are associated with the severity of COVID-19 disease in children, including older age and chronic co-morbidities such as obesity, diabetes and neurologic conditions.

By Jessica Pasley
Michael Harris works with Katherine Gilliland, FNP, during the recent transition of clinical and IT systems at Vanderbilt Tullahoma-Harton Hospital.
September 8, 2021

IT transition a success at Vanderbilt Tullahoma-Harton Hospital

Multiple teams from across Vanderbilt University Medical Center recently led a transition of the clinical and information technology (IT) systems at Vanderbilt Tullahoma-Harton Hospital.

By Madison Agee
Three-dimensional illustration of a coronavirus particle with a textured gray spherical surface, red spike proteins, and smaller yellow surface structures; blurred particles appear in the background.
September 2, 2021

Rheumatoid arthritis drug combined with standard of care may help reduce mortality for hospitalized COVID-19 patients

Hospitalized patients with COVID-19 who received the rheumatoid arthritis drug baricitinib, in combination with the standard of care including corticosteroids, died less often than those receiving only the standard of care, according to a study released this week in The Lancet Respiratory Medicine.

By Nancy Humphrey